A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Ovarian CancerSolid TumorMelanomaNon Small Cell Lung CancerPancreatic CancerPapillary Thyroid CancerColorectal Adenocarcinoma
- Interventions
- Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - ExpansionDrug: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - ExpansionDrug: Nivolumab, Nab paclitaxel and Gemcitabine - ExpansionDrug: CM-24 and Nivolumab - Dose Escalation
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Famewave Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT04731467
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
Phase 1
Terminated
- Conditions
- Bladder CancerOvarian CancerNon-small Cell Lung Carcinoma (NSCLC)MelanomaColorectal CancerGastric Cancer
- Interventions
- Biological: CM-24 (MK-6018)Biological: Pembrolizumab (MK-3475)
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Famewave Ltd.
- Target Recruit Count
- 27
- Registration Number
- NCT02346955
- Locations
- 🇺🇸
Call for Information (Investigational Site 0003), Los Angeles, California, United States
🇮🇱Merck Sharp & Dohme Co. Ltd., Hod Hasharon, Israel
🇺🇸Call for Information (Investigational Site 0004), New Haven, Connecticut, United States
© Copyright 2025. All Rights Reserved by MedPath